Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Blood. 2013 May 2;121(18):3727-32. doi: 10.1182/blood-2013-01-479576. Epub 2013 Feb 27.
Laboratory testing for heparin-induced thrombocytopenia (HIT) has important shortcomings. Immunoassays fail to discriminate platelet-activating from nonpathogenic antibodies. Specific functional assays are impracticable due to the need for platelets and radioisotope. We describe 2 assays that may overcome these limitations. The KKO-inhibition test (KKO-I) measures the effect of plasma on binding of the HIT-like monoclonal antibody KKO to platelet factor 4 (PF4)/heparin. DT40-luciferase (DT40-luc) is a functional test comprised of a B-cell line expressing FcγRIIa coupled to a luciferase reporter. We compared these assays to polyspecific and immunoglobulin (Ig)G-specific PF4/heparin enzyme-linked immunosorbent assays (ELISAs) in samples from 58 patients with suspected HIT and circulating anti-PF4/heparin antibodies. HIT was defined as a 4Ts score ≥ 4 and positive (14)C-serotonin release assay. HIT-positive plasma demonstrated greater mean inhibition of KKO binding than HIT-negative plasma (78.9% vs 26.0%; P < .0001) and induced greater luciferase activity (3.14-fold basal vs 0.96-fold basal; P < .0001). The area under the receiver-operating characteristic curve was greater for KKO-I (0.93) than for the polyspecific (0.82; P = .020) and IgG-specific ELISA (0.76; P = .0044) and for DT40-luc (0.89) than for the IgG-specific ELISA (P = .046). KKO-I and DT40-luc showed better discrimination than 2 commercially available immunoassays, are simple to perform, and hold promise for improving the specificity and feasibility of HIT laboratory testing.
实验室检测肝素诱导的血小板减少症(HIT)存在重要缺陷。免疫测定法无法区分血小板激活和非致病性抗体。由于需要血小板和放射性同位素,特异性功能测定法不切实际。我们描述了两种可能克服这些限制的检测方法。KKO 抑制试验(KKO-I)测量血浆对 HIT 样单克隆抗体 KKO 与血小板因子 4(PF4)/肝素结合的影响。DT40-荧光素酶(DT40-luc)是一种功能性检测方法,由表达 FcγRIIa 的 B 细胞系组成,与荧光素酶报告基因相连。我们比较了这两种检测方法与多特异性和免疫球蛋白(Ig)G 特异性 PF4/肝素酶联免疫吸附测定(ELISA)在 58 例疑似 HIT 和循环抗 PF4/肝素抗体的患者样本中的应用。HIT 的定义为 4Ts 评分≥4 分且阳性(14)C-血清素释放试验。HIT 阳性血浆的 KKO 结合抑制作用明显大于 HIT 阴性血浆(78.9% vs 26.0%;P<0.0001),并诱导更高的荧光素酶活性(基础值的 3.14 倍 vs 基础值的 0.96 倍;P<0.0001)。KKO-I 的受试者工作特征曲线下面积大于多特异性 ELISA(0.82;P=0.020)和 IgG 特异性 ELISA(0.76;P=0.0044),也大于 DT40-luc(0.89)和 IgG 特异性 ELISA(P=0.046)。KKO-I 和 DT40-luc 比两种市售免疫测定法具有更好的鉴别能力,操作简单,有望提高 HIT 实验室检测的特异性和可行性。